

February 26, 2014

STATEMENT ON A NONPROPRIETARY NAME ADOPTED BY THE USAN COUNCIL

USAN (AB-136)

DORGENMELTUCEL-L

PRONUNCIATION

dor'' jen mel too' sel - el

THERAPEUTIC CLAIM

Treatment of patients with refractory or recurrent
Melanoma

CHEMICAL DESCRIPTION

HyperAcute®-Melanoma is a live, whole cell immunotherapy product for use in patients diagnosed with melanoma that is produced by NewLink Genetics. The cancer vaccine consists of equal doses of three allogeneic human melanoma cancer cell lines (HAM1, HAM2 and HAM3) engineered to express the murine alpha-(1,3)-galactosyltransferase gene.

TRADEMARK

HyperAcute-Melanoma™

SPONSOR

New Links Genetics Corporation

CODE DESIGNATIONS

NLG-12036; HAM

SCS